March 26-28, 2019

Boston, USA

Speakers

Expand/Collapse

Carla Greenbaum
Director- Diabetes Program
Benaroya Research Institute

Carla Greenbaum MD is Director of the Diabetes Program at Benaroya Research Institute in Seattle WA.  She has expertise in clinical trial design and implementation and evaluation of biomarkers for disease course and response to therapy.  For more than 25 years, Dr. Greenbaum has conducted studies evaluating beta cell function and other physiologic and immune changes that occur during the progression of type 1 diabetes.  She currently serves as Chair of Diabetes TrialNet, an NIH-sponsored international multi-center clinical trial network aiming to bring disease-modifying therapy to clinical use.  Dr. Greenbaum received her medical degree at Brown University and underwent endocrinology fellowship training at University of Washington.

Day One

WEDNESDAY, MARCH 27, 2019

08.50 | Chair’s Opening Remarks

Day Two

THURSDAY, MARCH 28, 2019

13.30 | Lessons Learned from Multi-Center Trials of Antigen Therapy in T1D

Gerald (Jerry) Nepom
Director
Immune Tolerance Network

Dr. Nepom is Director of the Immune Tolerance Network (ITN), sponsored by the National Institutes of Health, and former Director and founder of the Benaroya Research Institute, in Seattle WA, USA.  His primary research interests focus on characterization of the human CD4 T cell response in autoimmunity, with an emphasis on type 1 diabetes (T1D), as well as the translation of immunological intervention strategies into innovative clinical trials.  His laboratory is credited with several advances in human autoimmunity, including initial descriptions of HLA class II disease associations, structure, and function, and the development of human class II tetramers for direct T cell detection and analysis. Dr. Nepom also serves as an advisor for many academic and nonprofit organizations involved in biomedical research and is past president of FOCIS, the Federation of Clinical Immunology Societies.  He has published over 350 scientific papers and received recognition through several awards, including the University of Washington School of Medicine Distinguished Alumni Award and the David Rumbough Award for Scientific Excellence from the Juvenile Diabetes Research Foundation.

Day One

WEDNESDAY, MARCH 27, 2019

09.00 | Antigen-Specific T Cell Profiles as Therapeutic Targets in Allergy and Autoimmune Disease

Day Two

THURSDAY, MARCH 28, 2019

15.00 | Combining Induction with Consolidation Therapy in ITN Clinical Trials for Autoimmunity

David Wraith
Institute Director of Immunology & Immunotherapy and Professor of Immunology
University of Birmingham

David Wraith is Professor of Immunology, Director of the Institute of Immunology and Immunotherapy at the University of Birmingham and CSO of Apitope NV, a company that designs and develops peptides for antigen-specific immunotherapy of allergic and autoimmune diseases. David began his career at NIMR, London, working on the immune response to viruses. He received MRC funding to study autoimmunity at Stanford University. This led to him establishing a Wellcome Trust funded research laboratory at the University of Cambridge and, between 1995 and 2016, he held the Chair in Experimental Pathology in Bristol. His research group is principally supported by the Wellcome Trust, MRC, EU-Innovative Medicines Initiative, Diabetes UK, Helmsley Trust and the Children’s Liver Disease Foundation.

Day One

WEDNESDAY, MARCH 27, 2019

09.30 | Antigen-Specific Immunotherapy for Treatment of Autoimmune Diseases

Amy Rosenberg
Supervisory Medical Officer and Division Director, Office of Biotechnology Products
CDER/FDA

Amy Rosenberg received her MD from Albert Einstein College of Medicine and is Board Certified in Internal Medicine. She was a post-doctoral fellow at NCI in Al Singer’s lab. She joined CBER, FDA in 1988, becoming Director of the Division of Therapeutic Proteins, CBER/CDER in 2000 (now DBRR3 in the Office of Biotechnology Products, CDER). She has been a driving force in risk evaluation and mitigation pertaining to the immunogenicity of therapeutic proteins (Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products) and in the elucidation and implementation of immune tolerance induction protocols in clinical settings. She co-edited the AAPS/Springer Book “Biobetters: Protein Engineering to Approach the Curative”.

Workshop C

TUESDAY, MARCH 26, 2019

14.30 | Considerations for Combination Strategies for Tolerizing Immunotherapies

Day Two

THURSDAY, MARCH 28, 2019

16.30 | Panel Discussion: Evaluation of Combination Therapies to Address Unmet Clinical Needs

Ranjeny Thomas
Professor of Rheumatology at University of Queensland; Director
Dendright

Professor Thomas is Professor of Rheumatology at University of Queensland, Translational Research Institute, consultant rheumatologist at Princess Alexandra Hospital and fellow of the Australian Academy of Health and Medical Sciences. Her research seeks to understand autoimmune disease and restoration of immune tolerance. Through this work, she developed and tested the first rheumatoid arthritis vaccine. She has also contributed major insights into how the microbiome is involved in causing spondyloarthropathy leading to the development of disease biomarkers and therapeutic strategies. Ranjeny is founder and a director of the spin-off company, Dendright, which is developing immunotherapy for autoimmune diseases.

Workshop C

TUESDAY, MARCH 26, 2019

14.30 | Considerations for Combination Strategies for Tolerizing Immunotherapies

Day One

WEDNESDAY, MARCH 27, 2019

14.30 | Antigen-Specific Tolerance Induction in Rheumatoid Arthritis

Erika von Mutius
Professor of Pediatric Allergology
Dr. von Hauner Children’s Hospital

Erika von Mutius is Professor of Pediatric Allergology and holds a degree in Epidemiology from Harvard School of Public Health, USA. Since 1993 she has been head of the Asthma and Allergy Department at the University Children’s Hospital in Munich and the Munich University Asthma and Allergy Research Group (www.asthma-allergy.de). Since 2017 she has furthermore been leading the Institute of Asthma and Allergy Prevention at Helmholtz Zentrum Muenchen, German Research Center for Environmental Health. She is a Fellow of the European Respiratory Society and a member of the Editorial Board of the New England Journal of Medicine. In June 2010 she was awarded the honorary doctorate from the University of Helsinki and in 2013 the Gottfried-Wilhelm-Leibniz Prize of the German Research Foundation which is the most important research award in Germany. Prof Dr von Mutius’ working group has been actively involved in design, implementation and data analysis of many large, Pan-European multicenter and interdisciplinary projects, including birth cohort studies, addressing the potential role of genetic and environmental factors for the development of asthma and allergic diseases. The group has furthermore developed expertise and gained excellence in the conduct of studies aiming at elucidating the role of microbial exposures for the development of allergies and asthma.

Day One

WEDNESDAY, MARCH 27, 2019

11.30 | Protection from Childhood Allergies & Inflammatory Bowel Disease

Jack Ragheb
Senior Medical Fellow for Immunology- Global Patient Safety
Eli Lilly

Dr. Ragheb has been with Lilly for about 2 years and is based in Indianapolis where he is the Senior Medical Fellow in Global Patient Safety and Co-Chair of the Immunogenicity Immunosafety Working Group. He received his MD and PhD degrees from the Johns Hopkins University and is a Diplomate of the American Board of Allergy & Immunology. Formerly, he was a Senior Clinical Investigator at NIH where he conducted clinical and basic research on immune tolerance and a Chief Medical Research Officer in the Office of Biological Products at the FDA where his research group established the BLT humanized mouse model in an effort to predict the immunogenicity of biotherapeutics. He has published in the areas of immunogenicity, immune tolerance, CD28 and CD40L regulation, retrovirology and gene therapy.

Day One

WEDNESDAY, MARCH 27, 2019

12.00 | Anti-Drug Antibody Responses: Past, Present & Future

Day Two

THURSDAY, MARCH 28, 2019

08.25 | Chair’s Opening Remarks

Robert (Bob) Anderson
CSO
ImmusanT

Dr Anderson’s career has focused on discovery and development of epitope-specific immunotherapy for celiac disease. His undergraduate and doctoral research was at Otago University in New Zealand. He trained as a specialist gastroenterologist at the Royal Melbourne Hospital in Australia, and then completed post-doctoral research in the Nuffield Department of Medicine at Oxford University supervised by Professors AV Hill and DP Jewell. His involvement in celiac disease began during that post-doctoral period with identification of the immuno-dominant epitope in A-gliadin. He is the lead inventor of the Nexvax2 technology. Before joining ImmusanT, Inc in 2012, he held appointments at the Walter and Eliza Hall Institute, and Alfred Hospital in Melbourne.

Day Two

THURSDAY, MARCH 28, 2019

13.00 | Immunotherapy for Celiac Disease Using Immuno-Dominant Gluten Epitopes (Nexvax2®) – Discovery to Phase 2

Michael Boyne
VP of Product Development & Analytics
Cour Pharmaceuticals

Michael Boyne, PhD. is an accomplished scientific professional. He leads CMC and research development activities for the Cour pipeline.  Before joining Cour, he was a Senior Consultant at BioTechLogic where he advised pharmaceutical manufacturers on drug development and CMC strategy, including drafting, reviewing, and authoring Pharmaceutical Quality/CMC sections (Module 3) of the CTD for regulatory submissions. Prior to consulting, he was a Research Chemist in the Division of Pharmaceutical Analysis at the US Food and Drug Administration where he established a laboratory developing and applying modern analytical technologies for the evaluation and regulation of complex drug products. Michael has authored over 40 peer-reviewed publications and is an internationally recognized speaker on the development of modern analytical technologies and their application to drug development. He is currently the chair of the 15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry and sits on the organizing committee for the CASSS meeting on Cell and Gene Therapies.

Day One

WEDNESDAY, MARCH 27, 2019

10.00 | Antigen Specific Approaches to Food Allergy & Immunogenicity

Julia Greenstein
VP- Research Strategy
JDRF

Julia Greenstein is the Vice President of Research Strategy at JDRF. She has been at JDRF for over 10 years beginning in the Beta cell portfolio and serving in a variety of roles in the Cure and Prevention portfolios. Previously she was CEO of Immerge BioTherapeutics, Inc., a Novartis Pharma/BioTransplant JV and has held the roles CSO at BioTransplant and VP of Discovery Research at ImmuLogic Pharmaceutical Corp. She received her PhD in Microbiology from University of Rochester Medical School.  She did postdoctoral training at the University of Rochester Medical School and the Dana Farber Cancer Institute of Harvard Medical School and was an Assistant Professor the Dana Farber Cancer Institute. In addition, she serves on the Board of Directors of The Sage Colleges and is on the University of Rochester Regional Cabinet.

Workshop A

TUESDAY, MARCH 26, 2019

08.30 | Improving the Translation of Antigen Specific Therapies into the Clinic Across Disease Indications

Antoon Van Oosterhout
VP & Head Allergic Inflammation Discovery Performance Unit
GSK

Antoon Van Oosterhout (PhD) is a highly experienced pharmaceutical based immunologist/ pharmacologist with a proven track record in Academia and Industry, leading multi-disciplinary teams in drug discovery and development. His ambition is to apply novel scientific findings to high unmet need immune-driven diseases with the aim to identify tractable targets and develop innovative game-changing therapeutic interventions. Joined GSK in 2013 as Vice President & Head of the Allergic Inflammation Discovery Performance Unit, responsible for a team of scientists aiming to discover novel therapies that change the course of asthma by driving asthma remission and to develop personalised medicines for improved control of severe asthmatics. Previously Antoon was Professor Immunology of Lung Diseases at the University Medical Centre Groningen with over 20 years’ experience in asthma research.  He completed his PhD and post-doctoral studies at Utrecht University and joined the Groningen Research Institute for Asthma and COPD after a sabbatical at Genentech, San Francisco.  He has authored over 150 publications in the field of respiratory diseases, allergy, immunology and pharmacology, with a focus on immunomodulation of allergic asthma.

Day One

WEDNESDAY, MARCH 27, 2019

14.00 | Targeting Dendritic Cells to Restore Immune Tolerance in Auto- Immune- & Allergic Diseases

Day Two

THURSDAY, MARCH 28, 2019

16.30 | Panel Discussion: Evaluation of Combination Therapies to Address Unmet Clinical Needs

Anne De Groot
CEO & CSO
EpiVax

Anne S. De Groot earned her bachelor’s degree at Smith College and her M.D. at the University of Chicago Pritzker School of Medicine, and then trained in Internal Medicine at New England Medical Center. She worked on field campaigns to vaccinate against measles in Zaire, was an NIH fellow in tropical medicine and vaccinology (NIAID, NCI) and underwent specialty training in infectious disease at New England Medical Center. De Groot was a faculty member at Brown University from 1993-2008, and established EpiVax, Inc.  with business partner Bill Martin in 1998. In addition to serving as CEO and CSO of EpiVax, she directs the Institute for Immunology and Informatics (iCubed) at the University of Rhode Island. She moved her academic affiliation to URI in 2008 and was awarded $13M in funding from the NIH to establish the Institute as a Center of Excellence in Computational Vaccinology (2009-2015). In addition to contributing to the discovery and validation of Tregitopes, De Groot was recognized as one of the 50 most influential people in vaccinology in 2014 and as Biotech CEO of the Year at the 9th Vaccine Industry Excellence Awards in 2016.

Day Two

THURSDAY, MARCH 28, 2019

15.30 | Tregitopes Induce Active Tolerance in Autoimmune Diabetes & Allergy

Timm Jessen
CEO
Topas Therapeutics

Day Two

THURSDAY, MARCH 28, 2019

10.30 | Preparation of Liver-Targeting Nanoparticles for Clinical Trials

Roland Martin
Head- Department of Neuroimmunology & Multiple Sclerosis Research Neurology Clinic
University Hospital Zurich, University Zurich

Trained in immunology, virology and neurology. Active in translational and basic research in cellular immunology and multiple sclerosis since 30 years. Research focus on antigen recognition, cellular immunology and development of novel treatments. Already conducted several clinical trials in the area of antigen-specific tolerance and the use of biologicals in multiple sclerosis.

Day One

WEDNESDAY, MARCH 27, 2019

15.00 | Target Identification in Immune-Mediated Disorders Including Autoimmune Diseases, Allergies, Anti-Drug Responses & Tumor Immunology

Charlotte Fribert
CEO
Toleranzi AB

Charlotte Fribert, CEO of Toleranzia, studied medicine at the Karolinska Institute and at the Pierre and Marie Curie University of Sorbonne in Paris, where she also obtained a PhD in immunology and biotechnology. Before Fribert began working at Toleranzia she worked as Project Director in drug development at AstraZeneca in Mölndal. Prior to this, she founded, developed and led Epixis SA, a vaccine development company based in Paris, which was successfully sold to VBI Vaccines Inc. in the US. Fribert has thus considerable experience both in Toleranzia’s therapy area and in the effective development of small life science companies.

Day One

WEDNESDAY, MARCH 27, 2019

17.00 | Panel Discussion: How to Identify & Prioritize the Route to Success for Antigen-Specific Immune Tolerance Induction Strategies?

16.00 | TOL2: An Antigen Specific Tolerogenic Therapy for the Treatment of Myasthenia Gravis

Kei Kishimoto
CSO
Selecta Biosciences

Dr. Kishimoto is the Chief Scientific Officer of Selecta Biosciences, a biotechnology company developing synthetic vaccines based on a novel self-assembling nanoparticle technology.  Prior to joining Selecta, Dr. Kishimoto was Vice President of Research at Momenta Pharmaceuticals where he led multidisciplinary teams in inflammation, oncology, and cardiovascular disease.  Previously he was Senior Director of Inflammation Research at Millennium Pharmaceuticals, where he provided the scientific leadership for four programs in clinical development, and an Associate Director of Immunology at Boehringer Ingelheim.  Dr. Kishimoto received his doctoral degree in Immunology from Harvard University and his post-doctoral training at Stanford University.

Day Two

THURSDAY, MARCH 28, 2019

12.30 | Preclinical & Clinical Development of Tolerogenic Nanoparticles to Mitigate Immunogenicity of Biotherapeutics

Stephen Miller
Co-founder of Cour Pharmaceutical; Professor of Microbiology-Immunology
Northwestern University Medical School

Dr. Stephen Miller is the Judy E. Gugenheim Research Professor of Microbiology-Immunology at Northwestern University Feinberg School of Medicine in Chicago.  He received his Ph.D. in 1975 from the Pennsylvania State University and did postdoctoral training at the University of Colorado Health Sciences Center before joining the faculty at Northwestern in 1981 where he currently serves as Director of the Northwestern University Interdepartmental Immunobiology Center.  Dr. Miller is internationally recognized for his research on pathogenesis and regulation of autoimmune diseases.  He has published over 410 journal articles, reviews and book chapters and has trained multiple generations of scientists. His work has significantly enhanced understanding of immune inflammatory processes underlying chronic autoimmune disease employing animal models of multiple sclerosis (MS) and Type 1 diabetes (T1D).  His work has focused on the study of the cellular and molecular mechanisms underlying treatment of established T cell-mediated autoimmune diseases using antigen-specific immune tolerance.  His current work is geared to translating the use of antigen-linked biodegradable PLG nanoparticles for the treatment of human immune-mediated diseases including autoimmunity, allergy and tissue/organ transplantation.

Day Two

THURSDAY, MARCH 28, 2019

08.30 | Mechanisms Underlying Tolerance Induction with Antigen- Encapsulating PLG Nanoparticles

Francisco Leon
CSO
Provention Bio

Francisco Leon, MD, PhD, an immunologist by training, is the co-founder and Chief Scientific Officer of Provention Bio, Inc (NASDAQ: PRVB). Previously, Dr. Leon was the co-founder, Chief Executive Officer and Chief Medical Officer of Celimmune, LLC, acquired by Amgen Inc. in 2017. Dr. Leon also served as Vice President and Head of Translational Medicine/Immunology at Johnson & Johnson’s Janssen Pharmaceuticals, and held early clinical research leadership positions at Alba Therapeutics, Medimmune and Bristol-Myers Squibb. Six drugs co-developed by Dr. Leon have made it to market, and he has published over 80 scientific articles.

Day Two

THURSDAY, MARCH 28, 2019

16.00 | Immune Modulation + Antigen Specificity: Exploring Combination Approaches for Tolerance Induction & Maintenance in Autoimmunity & Immunogenicity

Pieter Rottiers
CEO
ActoBio Therapeutics

Pieter Rottiers, PhD, is CEO of ActoBio Therapeutics, a wholly owned subsidiary of Intrexon Corporation and innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents. Dr. Rottiers is an entrepreneurial leader with over 15 years’ experience in drug discovery and development using the ActoBiotics platform, including over 13 years leadership and managerial experience in biopharmaceutical setting. Prior to Intrexon, Dr. Rottiers held several R&D and executive management functions at ActoGeniX, a company acquired by Intrexon beginning of 2015, where he was part of the founding team and progressed 3 ActoBiotics products from discovery research into clinical trials

Day Two

THURSDAY, MARCH 28, 2019

16.30 | Panel Discussion: Evaluation of Combination Therapies to Address Unmet Clinical Needs

Finola Moore
Associate Director of Immune Tolerance
SQZ Biotechnologies

Finola Moore, PhD is the Associate Director of Immune Tolerance at SQZ Biotech with a long-term interest in immunology and cancer biology. She leads the SQZ Tolerance team which aims to use the SQZ cell therapy platform to engineer the immune system for tolerance with application to diseases of autoimmunity.  Prior to joining SQZ, Dr. Moore conducted her post-doctoral studies at Massachusetts General Hospital and Harvard Medical School studying the effects of genes on cancer relapse in a T cell acute lymphoblastic leukemia model. Finola received her PhD in Oncology and Cancer Biology from Northwestern University.

Day One

WEDNESDAY, MARCH 27, 2019

16.30 | Engineering Red Blood Cells for Immune Tolerance Using Cell Squeeze® Technology

Day Two

THURSDAY, MARCH 28, 2019

16.30 | Panel Discussion: Evaluation of Combination Therapies to Address Unmet Clinical Needs

Matthias von Herrath
Professor at the La Jolla Institute for Allergy & Immunology; VP of T1D R&D Center Seattle
Novo Nordisk

Vice President at novoNordisk since 2012 responsible for type 1 and kidney complications R&D strategy. Professor at La Jolla institute (part time) MD from Freiburg medical school and postdoc in Virology at Scripps. 2006 ADA Outstanding scientific achievement award and 2014 German Langerhans Preis.

Day One

WEDNESDAY, MARCH 27, 2019

17.00 | Panel Discussion: How to Identify & Prioritize the Route to Success for Antigen-Specific Immune Tolerance Induction Strategies?

Day Two

THURSDAY, MARCH 28, 2019

11.00 | Obstacles for Bringing Antigenic Tolerance Induction to the Clinic

David Alleva
Executive Director- Immunotherapeutics
Akston Biosciences

David Alleva, Ph.D., has 20 years of experience as a scientific leader in drug discovery and development of immunotherapeutics & vaccines in several biopharmaceutical companies and has published over 30 research articles in peer-reviewed journals.  He developed one of the first antigen-specific immunotherapeutic clinical candidates for type 1 diabetes (T1D), an altered peptide ligand of insulin B9-23, and is currently involved with the early-stage biotech company, Akston Biosciences, focused on B cell immunotherapeutics for T1D.  He also led the T1D Immunotherapeutics program at the JDRF that drove a therapeutic research and development pipeline aimed at delivering novel therapies for the prevention and treatment of T1D.  This entailed creating strategies for developing innovative immunotherapies that included partnering with biotechnology and pharmaceutical companies, along with managing an academic research portfolio.

Day One

WEDNESDAY, MARCH 27, 2019

17.00 | Panel Discussion: How to Identify & Prioritize the Route to Success for Antigen-Specific Immune Tolerance Induction Strategies?

Day Two

THURSDAY, MARCH 28, 2019

09.00 | Antigen-Specific Targeting of B cells in Type 1 Diabetes

Joshua Sestak
President & CSO
Orion BioScience

Joshua Sestak, PhD (President & CSO of Orion BioScience Inc): Before founding Orion BioScience, Joshua had both industrial and academic roles.  Joshua graduated with a degree in chemistry and biochemistry from Gonzaga University in Spokane, WA. Afterward he worked as a formulations research associate at Nastech Pharmaceutical in Bothell, WA, and developed nasally delivered peptide therapies and siRNA formulations to treat diabetes, obesity, and autism.  Joshua left industry to attend the University of Kansas and complete his Ph.D in Pharmaceutical Chemistry.  While at KU he was a dual Madison and Lila Self Graduate Fellow and Institute for Advancing Medical Innovation (IAMI) Graduate Fellow.  Joshua his advisor Cory Berkland co-founded Orion BioScience in 2012.  He has multiple patents and numerous publications focused on developing therapies to suppress autoimmune disease and reintroduce tolerance through the use of antigen specific immunotherapies.

Day One

WEDNESDAY, MARCH 27, 2019

17.00 | Panel Discussion: How to Identify & Prioritize the Route to Success for Antigen-Specific Immune Tolerance Induction Strategies?

Day Two

THURSDAY, MARCH 28, 2019

09.30 | Soluble Antigen Arrays’ Mimic Peripheral Tolerance to Intercept Autoimmune Disease and Restore Health

Simi Ahmed
Director, Research
JDRF

Simi T. Ahmed, Ph.D., is a Director of Research and lead of the Immune Therapies Program at JDRF. She is responsible for creating and implementing the vision and strategy of this program, with core emphasis on the establishment of effective disease modifying immunotherapies for T1D. Her experiences range from basic research to translational medicine, and draw from effective partnerships within the public and private sectors. Prior to joining JDRF, Dr. Ahmed completed her postdoctoral training in Dr. James E. Darnell’s laboratory at The Rockefeller University in New York. She holds a bachelor’s degree in Biophysical Chemistry from Dartmouth College and a doctorate in Immunology from the Weill Graduate School of Medical Sciences of Cornell University.

Workshop A

TUESDAY, MARCH 26, 2019

08.30 | Improving the Translation of Antigen Specific Therapies into the Clinic Across Disease Indications

Andreas Lutterotti
MD; Assistant Professor- Experimental Therapy Research in Multiple Sclerosis
University of Zurich

Andreas Lutterotti is assistant professor for "Experimental Therapy Research in Multiple Sclerosis and Other Neurological Diseases" at the University of Zurich since August 2014, as well as a senior physician at the Department of Neurology, Section Neuroimmunology and MS Research (nims), University Hospital Zurich. He has earned his medical doctor's degree at the Medical University in the Clinical Department of Neurology, Innsbruck and was certified in Neurology in 2012. His core expertise is the development and implementation of experimental therapies in the field of multiple sclerosis and other autoimmune diseases. He is Co-Founder of Cellerys AG, a company developing a cell based therapy to induce immune tolerance in MS.  

Workshop B

TUESDAY, MARCH 26, 2019

11.30 | Antigen-Specific Tolerance Induction: Robust Strategies to Improve Clinical Trials Efficacy & Success Rate

Yoav Messinger
Medical Director- Cancer and Blood Disorders
Children’s Hospitals and Clinics of Minnesota

Yoav Messinger, MD is the Medical Director of the Cancer and Blood Disorders (Pediatric Hematology/Oncology) at Children’s Hospitals of Minnesota, Minneapolis, Minnesota. He has collaborated with the first successful strategy of tolerance induction in Infantile Pompe disease. He has many years of experience with the use of B-cell directed agents such as rituximab and bortezomib.

Day Two

THURSDAY, MARCH 28, 2019

14.30 | Long-Term Consequences of Tolerance Induction Strategies Using Anti- B-Cell (Rituximab), Especially to the Growing Child: Lessons Learned from Oncology & Pompe Disease

14.00 | Long-Term Consequences of Tolerance Induction Strategies Using AntiB-Cell (Rituximab), Especially to the Growing Child: Lessons Learned from Oncology & Pompe Disease

Xunrong Luo
Director-Translational Research
Duke Transplant Center, Duke University

Dr. Luo earned her MD and PhD degrees from Duke University, then completed an internship and residency in internal medicine at the New York-Presbyterian Weill Cornell Medical Center, followed by a clinical fellowship in Nephrology and a research fellowship in Transplant Nephrology also at Weill Cornell.  Luo’s research primarily focuses on the induction and mechanisms of transplantation tolerance, using innovative donor-specific negative vaccination strategies to target the host machineries involved in clearance of cellular apoptotic debris in an immunotolerogenic manner.  She also investigates the engineering of biosynthetic platforms with tolerogenic signals for potentially “off-the-shelf” tolerance treatment options for transplant recipients.  The novelty and significance of her work is underscored by continuous funding of her research, her numerous awards, and her recent induction into the prestigious American Society of Clinical Investigation.

Day One

WEDNESDAY, MARCH 27, 2019

12.30 | Antigen-Specific Tolerance for Transplantation

Lotta Jansson
Chief Research Officer
Apitope

Lotta Jansson is Chief Research Officer at Apitope International NV, Diepenbeek, Belgium.  She gained her PhD at Uppsala University in 1994 and continued an academic career at Lund University for the following 5 years. In 2013, she joined Apitope at the position as Research Director from AstraZeneca where she for the previous 13 years had held leading scientific positions within areas of autoimmunity and inflammation, inflammatory bowel disease (IBD) and neuroscience at research sites located in Sweden and United Kingdom. Dr Jansson has more than 50 scientific peer reviewed publications and patents.

Day One

WEDNESDAY, MARCH 27, 2019

17.00 | Panel Discussion: How to Identify & Prioritize the Route to Success for Antigen-Specific Immune Tolerance Induction Strategies?

Day Two

THURSDAY, MARCH 28, 2019

16.30 | Panel Discussion: Evaluation of Combination Therapies to Address Unmet Clinical Needs